LCT Scientific Panel - Living Cell Technologies

Targeting Huntington's Disease, Stroke, Type 1 Diabetes and Haemophilia

Information about LCT Living Cell Technologies

Archive

June 5, 2008

LCT Expands Diabetes Clinical Trial

>more

June 3, 2008

LCT Lists on International OTCQX

>more

May 21, 2008

LCT interviewed by New Zealand TV program, Close Up

>video

May 12, 2008

LCT presents encapsulation technology at conference

>more

May 8, 2008

LCT features on Channel Ten News

>more

>video

May 8, 2008

LCT prepares to list on international OTCQX

>more

History Board of Directors Scientific Panel Team Career Opportunities

Scientific Panel

The Scientific Committee has been formed and is responsible for review and reporting to the Board of:

Scientific developments and improvements
Regulatory matters associated with the science
Feasibility of commercialisation and research of existing and new products, and
Patents and other intellectual property developments

The Scientific Committee is chaired by an independent adviser to the Board. The CEO is not a member of the Scientific Committee.

Dr John Court MB, BS, FRACP, Panel Chairman
Private consultant practice in paediatric and adolescent medicine in Melbourne, Australia.

What is xenotransplantation?
The use of living animal cells, tissues or organs in human therapeutics. >more

What is DiabeCell?
DiabeCell is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. >more

What is NeurotrophinCell?
A choroid plexus (brain) cell product with the potential to treat diseases of the nervous system such as Huntington's disease and stroke. >more

What is LCT's encapsulation technology?
The living cells are covered in a seaweed-derived coating (alginate encapsulation) to form capsules which eliminate the
need for toxic immunosuppressant drugs and allow the release of beneficial factors. >more

	Home Contact Sitemap Legals Privacy
graphic design and website design - PDF Communications Ltd